Leveraging Active Diagnostic Stewardship Interventions to Optimize the Outcomes of Patients with Bacteremia

Bloodstream infections are a common cause of morbidity and mortality despite advances in antimicrobial agents and sepsis management. Over the past decade, several molecular methods have been integrated into routine clinical microbiology workflows due to their ability to rapidly and simultaneously detect microorganisms and antimicrobial resistance genes from positive blood cultures.

Incorporating a rapid multiplex molecular blood culture identification (BCID) panel can be an important strategy to improve the outcomes of patients with bacteremia and improve antimicrobial utilization. However, the impact on clinical outcomes is only realized when rapid BCID results are partnered with active stewardship interventions.

In this webinar, the expert speaker will share insights gained through the implementation of a rapid syndromic cobas® eplex BCID panels in tandem with real-time antimicrobial stewardship interventions, which resulted in improved antimicrobial use and patient outcomes at a large academic medical center.

This webinar focuses on the integration of rapid blood culture identification into an antimicrobial stewardship program, how antimicrobial stewardship programs make rapid BCID results actionable and how the results can be used to demonstrate the value of the test and impact on antimicrobial stewardship.

Register for this webinar today to understand how active diagnostic stewardship interventions can help optimize the outcomes of patients with bacteremia.

Speaker

Ryan Shields, PharmD, MS, Associate Professor of Medicine, University of Pittsburgh, Department of Medicine

Ryan Shields is an Infectious Diseases pharmacist and Associate Professor in the Department of Medicine, Division of Infectious Diseases. He serves as the Director of UPMC Presbyterian Antibiotic Management Program and Co-Director of the Center for Innovative Antimicrobial Therapy at the University of Pittsburgh. Dr. Shields is also the Founder and Co-Director of the PRECEDENT network, a real-world comparative-effectiveness research network. He is actively engaged in the diagnosis and management of patients infected by multi-drug resistant bacteria. His laboratory focuses on the characterization and suppression of antimicrobial resistance by using molecular markers to predict patient responses and PK-PD pre-clinical models to study novel antibiotic approaches. Dr. Shields’ clinical and research roles have focused on designing individualized treatment regimens for patients infected by MDR pathogens, the emergence of resistance to new antimicrobial agents and developing innovative stewardship approaches to implement molecular diagnostic tests.

Message Presenter